WHO ICTRP trial
Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive…
NL-OMON31602 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON31602 |
|---|---|
| Public title | Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide in patients with newly diagnosed glioblastoma |
| Scientific title | Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide in patients with newly diagnosed glioblastoma - RTOG 0525 / EORTC 26052-22053 |
| Primary sponsor | European Organisation for Research in Treatment of Cancer (EORTC) |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | braintumour Glioblastoma;10029211;10029211;10009720;braintumour;Glioblastoma |
| Interventions | In both treatmentarms patients will have radiation of the primary tumour area ( 60 Gy in 2 Gy fractions) combined with daily temozolomide ( 75 mg/m2) , during maximum 49 days, followed by adjuvant chemotherapy: * Conventional arm… |
| Registration date | May 2, 2012 |
| Target size | 100 |
| Secondary IDs | 2005-005177-29;NCT00304031;NL13696.028.06 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: